Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 1998 Oct;74(5):316–322. doi: 10.1136/sti.74.5.316

Pathogenesis and treatment of HTLV-I associated myelopathy

G P Taylor
PMCID: PMC1758138  PMID: 10195025

Abstract

That HTLV-I is not a latent infection is indicated by the detection of mRNA in the peripheral blood and CNS of patients with HTLV-I infection and by the persisting humoral and cellular immune responses. Indeed the frequency of anti-HTLV CTL is extremely high. The reduction in anti-TAX CTL frequency following reduction in proviral load suggests that removal of viral antigen may result in a reduced inflammatory response at least in peripheral blood and although the clinical data should be interpreted with caution, perhaps in the CNS. Patients with more advanced disease, and possibly fixed deficits may not benefit from either anti-inflammatory or antiretroviral treatment. The patients with most to gain are those with least deficit in whom early diagnosis and treatment will depend on raising awareness of HTLV-I beyond the neurological community. Many patients with HAM first present to a urologist or gynaecologist with bladder dysfunction or may have been seen in the genitourinary clinical with impotence or positive treponemal serology, which in the older patient is often the result of childhood infection with Treponema pallidum pertenue. Investigation of these patients should include HTLV-I serology and further investigation of HTLV-I positive patients should include proviral load measurements as well as markers of inflammation. Treatments whether antiviral or anti-inflammatory should be assessed for their effect on both as well as a clinical response. 




Full Text

The Full Text of this article is available as a PDF (163.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biddison W. E., Kubota R., Kawanishi T., Taub D. D., Cruikshank W. W., Center D. M., Connor E. W., Utz U., Jacobson S. Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol. 1997 Aug 15;159(4):2018–2025. [PubMed] [Google Scholar]
  2. CRUICKSHANK E. K. A neuropathic syndrome of uncertain origin; review of 100 cases. West Indian Med J. 1956 Sep;5(3):147–158. [PubMed] [Google Scholar]
  3. Cartier L. M., Cea J. G., Vergara C., Araya F., Born P. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropathol Exp Neurol. 1997 Apr;56(4):403–413. doi: 10.1097/00005072-199704000-00009. [DOI] [PubMed] [Google Scholar]
  4. Daenke S., Bangham C. R. Do T cells cause HTLV-1-associated disease?: a taxing problem. Clin Exp Immunol. 1994 May;96(2):179–181. doi: 10.1111/j.1365-2249.1994.tb06538.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Daenke S., Parker C. E., Niewiesk S., Newsom-Davis J., Nightingale S., Bangham C. R. Spastic paraparesis in a patient carrying defective human T cell leukemia virus type I (HTLV-I) provirus sequences but lacking a humoral or cytotoxic T cell response to HTLV-I. J Infect Dis. 1994 Apr;169(4):941–943. doi: 10.1093/infdis/169.4.941. [DOI] [PubMed] [Google Scholar]
  6. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 1995 Nov 15;86(10):3619–3639. [PubMed] [Google Scholar]
  7. Gessain A., Barin F., Vernant J. C., Gout O., Maurs L., Calender A., de Thé G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985 Aug 24;2(8452):407–410. doi: 10.1016/s0140-6736(85)92734-5. [DOI] [PubMed] [Google Scholar]
  8. Gout O., Gessain A., Iba-Zizen M., Kouzan S., Bolgert F., de Thé G., Lyon-Caen O. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol. 1991 Apr;238(2):108–109. doi: 10.1007/BF00315691. [DOI] [PubMed] [Google Scholar]
  9. Harrington W. J., Jr, Sheremata W. A., Snodgrass S. R., Emerson S., Phillips S., Berger J. R. Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses. 1991 Dec;7(12):1031–1034. doi: 10.1089/aid.1991.7.1031. [DOI] [PubMed] [Google Scholar]
  10. Hinuma Y., Nagata K., Hanaoka M., Nakai M., Matsumoto T., Kinoshita K. I., Shirakawa S., Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476–6480. doi: 10.1073/pnas.78.10.6476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Höllsberg P. Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurol Scand Suppl. 1997;169:86–93. doi: 10.1111/j.1600-0404.1997.tb08156.x. [DOI] [PubMed] [Google Scholar]
  12. Ichinose K., Nakamura T., Kawakami A., Eguchi K., Nagasato K., Shibayama K., Tsujihata M., Nagataki S. Increased adherence of T cells to human endothelial cells in patients with human T-cell lymphotropic virus type I-associated myelopathy. Arch Neurol. 1992 Jan;49(1):74–76. doi: 10.1001/archneur.1992.00530250078019. [DOI] [PubMed] [Google Scholar]
  13. Iwasaki Y., Ohara Y., Kobayashi I., Akizuki S. Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol. 1992 May;140(5):1003–1008. [PMC free article] [PubMed] [Google Scholar]
  14. Izumo S., Goto I., Itoyama Y., Okajima T., Watanabe S., Kuroda Y., Araki S., Mori M., Nagataki S., Matsukura S. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology. 1996 Apr;46(4):1016–1021. doi: 10.1212/wnl.46.4.1016. [DOI] [PubMed] [Google Scholar]
  15. Jacobson S., Shida H., McFarlin D. E., Fauci A. S., Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 1990 Nov 15;348(6298):245–248. doi: 10.1038/348245a0. [DOI] [PubMed] [Google Scholar]
  16. Jeannel D., Garin B., Kazadi K., Singa L., de Thé G. The risk of tropical spastic paraparesis differs according to ethnic group among HTLV-I carriers in Inongo, Zaire. J Acquir Immune Defic Syndr. 1993 Jul;6(7):840–844. [PubMed] [Google Scholar]
  17. Kaplan J. E., Osame M., Kubota H., Igata A., Nishitani H., Maeda Y., Khabbaz R. F., Janssen R. S. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr. 1990;3(11):1096–1101. [PubMed] [Google Scholar]
  18. Kataoka A., Imai H., Inayoshi S., Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1213–1216. doi: 10.1136/jnnp.56.11.1213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kinoshita T., Tsujimoto A., Shimotohno K. Sequence variations in LTR and env regions of HTLV-I do not discriminate between the virus from patients with HTLV-I-associated myelopathy and adult T-cell leukemia. Int J Cancer. 1991 Feb 20;47(4):491–495. doi: 10.1002/ijc.2910470403. [DOI] [PubMed] [Google Scholar]
  20. Kira J., Fujihara K., Itoyama Y., Goto I., Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci. 1991 Nov;106(1):41–49. doi: 10.1016/0022-510x(91)90192-a. [DOI] [PubMed] [Google Scholar]
  21. Kubota R., Fujiyoshi T., Izumo S., Yashiki S., Maruyama I., Osame M., Sonoda S. Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy. J Neuroimmunol. 1993 Feb;42(2):147–154. doi: 10.1016/0165-5728(93)90004-i. [DOI] [PubMed] [Google Scholar]
  22. Kuroda Y., Kurohara K., Fujiyama F., Takashima H., Endo C., Matsui M., Neshige R., Kakigi R. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand. 1992 Jul;86(1):82–86. doi: 10.1111/j.1600-0404.1992.tb08059.x. [DOI] [PubMed] [Google Scholar]
  23. Kuroda Y., Takashima H., Ikeda A., Endo C., Neshige R., Kakigi R., Shibasaki H. Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol. 1991 Sep;238(6):309–314. doi: 10.1007/BF00315327. [DOI] [PubMed] [Google Scholar]
  24. Lehky T. J., Fox C. H., Koenig S., Levin M. C., Flerlage N., Izumo S., Sato E., Raine C. S., Osame M., Jacobson S. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol. 1995 Feb;37(2):167–175. doi: 10.1002/ana.410370206. [DOI] [PubMed] [Google Scholar]
  25. MONTGOMERY R. D., CRUICKSHANK E. K., ROBERTSON W. B., MCMENEMEY W. H. CLINICAL AND PATHOLOGICAL OBSERVATIONS ON JAMAICAN NEUROPATHY; A REPORT ON 206 CASES. Brain. 1964 Sep;87:425–462. doi: 10.1093/brain/87.3.425. [DOI] [PubMed] [Google Scholar]
  26. Matsuo H., Nakamura T., Shibayama K., Nagasato K., Tsujihata M., Nagataki S. Long-term follow-up of immunomodulation in treatment of HTLV-I-associated myelopathy. Lancet. 1989 Apr 8;1(8641):790–790. doi: 10.1016/s0140-6736(89)92613-5. [DOI] [PubMed] [Google Scholar]
  27. Matsuo H., Nakamura T., Tsujihata M., Kinoshita I., Satoh A., Tomita I., Shirabe S., Shibayama K., Nagataki S. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet. 1988 Nov 12;2(8620):1109–1113. doi: 10.1016/s0140-6736(88)90525-9. [DOI] [PubMed] [Google Scholar]
  28. Misra A. K., Mishra S. K., Eigen A. C., Tourtellotte W. W. Successful immunosuppressive therapy for HTLV-I associated myelopathy. J Neurol Sci. 1994 Apr;122(2):155–156. doi: 10.1016/0022-510x(94)90293-3. [DOI] [PubMed] [Google Scholar]
  29. Moritoyo T., Reinhart T. A., Moritoyo H., Sato E., Izumo S., Osame M., Haase A. T. Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Ann Neurol. 1996 Jul;40(1):84–90. doi: 10.1002/ana.410400114. [DOI] [PubMed] [Google Scholar]
  30. Murphy E. L., Fridey J., Smith J. W., Engstrom J., Sacher R. A., Miller K., Gibble J., Stevens J., Thomson R., Hansma D. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology. 1997 Feb;48(2):315–320. doi: 10.1212/wnl.48.2.315. [DOI] [PubMed] [Google Scholar]
  31. Nagasato K., Nakamura T., Ichinose K., Nishiura Y., Ohishi K., Shibayama K., Watanabe H., Tsujihata M., Nagataki S. Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy: a preliminary study. J Neurol Sci. 1993 Apr;115(2):161–168. doi: 10.1016/0022-510x(93)90220-s. [DOI] [PubMed] [Google Scholar]
  32. Nakagawa M., Nakahara K., Maruyama Y., Kawabata M., Higuchi I., Kubota H., Izumo S., Arimura K., Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol. 1996 Oct;2(5):345–355. doi: 10.3109/13550289609146899. [DOI] [PubMed] [Google Scholar]
  33. Nakamura T., Shibayama K., Nagasato K., Matsuo H., Tsujihata M., Nagataki S. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy. Jpn J Med. 1990 Jul-Aug;29(4):362–367. doi: 10.2169/internalmedicine1962.29.362. [DOI] [PubMed] [Google Scholar]
  34. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986 May 3;1(8488):1031–1032. doi: 10.1016/s0140-6736(86)91298-5. [DOI] [PubMed] [Google Scholar]
  35. Parker C. E., Nightingale S., Taylor G. P., Weber J., Bangham C. R. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol. 1994 May;68(5):2860–2868. doi: 10.1128/jvi.68.5.2860-2868.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep;13(1):68–77. doi: 10.1097/00042560-199609000-00010. [DOI] [PubMed] [Google Scholar]
  37. Sheremata W. A., Benedict D., Squilacote D. C., Sazant A., DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology. 1993 Oct;43(10):2125–2129. doi: 10.1212/wnl.43.10.2125. [DOI] [PubMed] [Google Scholar]
  38. Shibayama K., Nakamura T., Nagasato K., Shirabe S., Tsujihata M., Nagataki S. Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects. J Neurol Sci. 1991 Dec;106(2):186–192. doi: 10.1016/0022-510x(91)90256-7. [DOI] [PubMed] [Google Scholar]
  39. Shirabe S., Nakamura T., Tsujino A., Nishiura Y., Furuya T., Goto H., Suenaga A., Nakane S., Yoshimura T., Nagataki S. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci. 1997 Oct 3;151(1):97–101. doi: 10.1016/s0022-510x(97)00074-9. [DOI] [PubMed] [Google Scholar]
  40. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977 Sep;50(3):481–492. [PubMed] [Google Scholar]
  41. Wattel E., Cavrois M., Gessain A., Wain-Hobson S. Clonal expansion of infected cells: a way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 (Suppl 1):S92–S99. doi: 10.1097/00042560-199600001-00016. [DOI] [PubMed] [Google Scholar]
  42. Yamasaki K., Kira J., Koyanagi Y., Kawano Y., Miyano-Kurosaki N., Nakamura M., Baba E., Suzuki J., Yamamoto A., Yamamoto N. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci. 1997 Apr 15;147(2):135–144. doi: 10.1016/s0022-510x(96)05319-1. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES